Humoral immune response to keyhole limpet haemocyanin, the protein carrier in cancer vaccines

11Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Keyhole limpet haemocyanin (KLH) appears to be a promising protein carrier for tumor antigens in numerous cancer vaccine candidates. The humoral immune response to KLH was characterized at the single-cell level with ELISPOT combined with separations of cell populations according to their expression of homing receptors (HRs). The analysis of HR expressions is expected to reveal the targeting of the immune response in the body. Eight orally primed and four nonprimed volunteers received KLH-vaccine subcutaneously. Circulating KLH-specific plasmablasts were found in all volunteers, 60 KLH-specific plasmablasts/106 PBMC in the nonprimed and 136/106 in the primed group. The proportion of L-selectin+ plasmablasts proved high and integrin 4 7 + low. KLH serving as protein carrier in several vaccines, the homing profile of KLH-specific response may be applicable to the cancer antigen parts in the same vaccines. The present data reflect a systemic homing profile, which appears advantageous for the targeting of immune response to cancer vaccines. Copyright © 2011 A. Kantele et al.

Cite

CITATION STYLE

APA

Kantele, A., Häkkinen, M. P., Zivny, J., Elson, C. O., Mestecky, J., & Kantele, J. M. (2011). Humoral immune response to keyhole limpet haemocyanin, the protein carrier in cancer vaccines. Clinical and Developmental Immunology, 2011. https://doi.org/10.1155/2011/614383

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free